A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
ClinicalTrials.gov Identifier: NCT04894890
Novartis Reference Number: CAIN457ACN06
Last Update: May 17, 2022
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
This non-interventional, prospective, multi-center study aims to provide short- and long- term treatment patterns, effectiveness, and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis (with and without PsA) initiating treatment of secukinumab.
Interventions
Eligibility Criteria
Inclusion Criteria:
Aged ≥ 18 years;
Diagnosis of clinically moderate to severe plaque-psoriasis;
Initiating treatment with secukinumab during the identification period or within 30 days prior to the index date;
Patient agrees to sign the informed consent
Exclusion Criteria:
- Participation in any dermatology or rheumatology clinical trial, concurrent or within the last 30 days of the secukinumab initiating date
Study Locations
Contacts
Have a question?
Call 1-888-669-6682 or email [email protected]